Periodic Reporting for period 1 - HYDROBLOOD (Innovative processing plant for optimal production of Decolourised Hydrolysed Protein (DHP). A secure, cost-effective and eco-friendly blood by-product solution.)
Período documentado: 2016-07-01 hasta 2016-12-31
Blood is a common by-product of the meat industry, which is obtained in large volumes especially in industrial slaughterhouses. Approximately 1,452 million pigs were processed worldwide for their meat in 2013. The annual available blood supply exceeds 4.35 million tonnes worldwide. Taking into account a typical protein content around 18%, 783k tonnes of protein could be produced worldwide.
In spite of the significance of this sum, an important part of the collected blood is not considered but a waste. The reason lies in the lack of suitable facilities in the slaughterhouses to properly collect and handle blood. Hence, a high percentage of the abovementioned amount of protein becomes a waste, which requires expensive decontamination treatments and large amounts of water. On the other hand, the collection of blood in most of the slaughterhouses where it is considered a by-product is carried out together with other by-products, treated un-specifically in large digesters. This process avoids part of the costs of elimination because it excludes the decontamination treatments, but the obtained end-product does not have a remarkable added value and the possibility of valorisation remains unexploited.
From TALLERES AZUARA we have identified the business opportunity behind this market weaknesses, and we have developed the HYDROBLOOD processing plant to solve all of them, which is a secure, cost-effective and eco-friendly system for blood collection and processing. With current technologies available into the market, only around 35% of the protein contained in blood can be recovered as an added-value by-product. With our innovative HYDROBLOOD processing plant, the 100% of protein content can be recovered from animal’s blood, and converted into a high added-value product: The Decolourised Hydrolysed Protein (DHP). This will make a big impact within the European Protein Market, valued at 2,547,000 Mt in 2013, and estimated to increase by more than 40% the next 10 years.
In spite of the significance of this sum, an important part of the collected blood is not considered but a waste. The reason lies in the lack of suitable facilities in the slaughterhouses to properly collect and handle blood. Hence, a high percentage of the abovementioned amount of protein becomes a waste, which requires expensive decontamination treatments and large amounts of water. On the other hand, the collection of blood in most of the slaughterhouses where it is considered a by-product is carried out together with other by-products, treated un-specifically in large digesters. This process avoids part of the costs of elimination because it excludes the decontamination treatments, but the obtained end-product does not have a remarkable added value and the possibility of valorisation remains unexploited.
From TALLERES AZUARA we have identified the business opportunity behind this market weaknesses, and we have developed the HYDROBLOOD processing plant to solve all of them, which is a secure, cost-effective and eco-friendly system for blood collection and processing. With current technologies available into the market, only around 35% of the protein contained in blood can be recovered as an added-value by-product. With our innovative HYDROBLOOD processing plant, the 100% of protein content can be recovered from animal’s blood, and converted into a high added-value product: The Decolourised Hydrolysed Protein (DHP). This will make a big impact within the European Protein Market, valued at 2,547,000 Mt in 2013, and estimated to increase by more than 40% the next 10 years.
We have taken opportunity of the financial support of Phase 1 to complete a feasibility study that has allowed us to fully validate the feasibility of reaching the market with our innovative HYDROBLOOD process and the non-precedent product obtained from it, the DHP. The study has covered the technological feasibility, market trends, and definition of the business model of HYDROBLOOD. The needs of different segments of end users and customers have been taken into account, which has led us to better define the concept presented in the phase 1 proposal in both, technical and business model, points of view. The technical and commercial risks for implementation have been fully assessed, and a contingency plan have been defined to minimize them. The project associated work plan has been fully defined, as well as the required investment for its execution. We have fully assessed our operational capacity to complete the envisaged project, and have secured external expertise where needed for the next phase. Based on market assessment results we have foreseen the sales for the next 10 years after the end of the project, in Europe (first 5 years) and worldwide.
The results of the feasibility study undertaken during the phase 1 action have endorsed our purpose to pursue the further development of the concept, following the revision of the specifications and update of the business model.
With our secure, cost-effective and eco-friendly system for blood collection and processing ready for its introduction in the food, animal feed, and protein markets, sales and net profit of TALLERES AZUARA after 2023 will grow beyond present estimates, opening several new regional/national/international markets, already interested in the protein production from animal blood, and its use as additive for animal and human consumption purposes.
With our secure, cost-effective and eco-friendly system for blood collection and processing ready for its introduction in the food, animal feed, and protein markets, sales and net profit of TALLERES AZUARA after 2023 will grow beyond present estimates, opening several new regional/national/international markets, already interested in the protein production from animal blood, and its use as additive for animal and human consumption purposes.